Is there a difference between biomarker cardiovascular risk assessment for broad population studies vs the role in personalized medicine? And, in individual patients, if a difference is found between the Framingham score and the biomarker risk assessment, which is more likely to correctly predict risk? Host Dr. Alan Brown talks with Dr. Michael Davidson, director of preventive cardiology and associate vice chairman for continuing medical education at the University of Chicago, about the role of biomarkers in improving cardiovascular risk prediction and guiding treatment, compared to traditional risk factor assessment.
Biomarkers and Lipidology
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Overview
Is there a difference between biomarker cardiovascular risk assessment for broad population studies vs the role in personalized medicine? And, in individual patients, if a difference is found between the Framingham score and the biomarker risk assessment, which is more likely to correctly predict risk? Host Dr. Alan Brown talks with Dr. Michael Davidson, director of preventive cardiology and associate vice chairman for continuing medical education at the University of Chicago, about the role of biomarkers in improving cardiovascular risk prediction and guiding treatment, compared to traditional risk factor assessment.
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
Recommended
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?